Skip to main content

Table 3 Infections in the Q1W and Q2W cohorts

From: Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data

  Q1W (N = 11)a Q2W (N = 13)b Difference (90% CI)
Number of patients with at least 1 infection (%) 6 (54.5%) 10 (76.9%) RR = 1.53 (0.91–2.59)
Total number of non-SBI (annualized rate) 8 (1.52c) 35 (2.68) IRR = 1.09 (0.72–1.67)
Number of patients treated with antibiotic therapy due to infection n.a. 8 (61.5%) n.a.
Days of antibiotic exposure per patientd n.a. 18.9 ± 13.5 (18; 9.25–24.25) n.a.
  1. The annual rate was calculated as described in the Methods section. Data on antibiotic therapy due to infections were not available in the SHIFT study. Days on antibiotic therapy are reported as the mean ± SD (median; interquartile range)
  2. IRR incidence rate ratio, RR risk ratio, SBI serious bacterial infection
  3. aIn the Q1W group, 4 patients were not considered, as data on their infections were not available
  4. bIn Q2W, all patients were considered, but as one patient switched to weekly SCIG therapy at 261 days after enrollment, the relevant infections were considered until only that date and not for 365 days
  5. cAnnualized rate is calculated in patients with available follow-up lengths (n = 4)
  6. dTime of antibiotic exposure per patient was calculated among only those (n = 8) who received antibiotics